Michael J Boyer

11PUBLICATIONS
71CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Dec 17, 2025
Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.

Meghana Maddula, Annelise Decaria, Bea Brown

|Aug 29, 2024
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.

Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat

|Jul 25, 2024
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.

Michael Boyer, Rina Hui, Damien Urban

|Mar 13, 2024
Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma and the Immune System: Pathogenesis, Immunotherapy and Future Perspectives.

A Khoo, M Boyer, Z Jafri

|Jan 11, 2024
Personalised Medicine and the Potential Role of Electrospinning for Targeted Immunotherapeutics in Head and Neck Cancer.

Connor H O'Meara, Thanh Vinh Nguyen, Zuhayr Jafri

|Jun 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.

Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard

Pageof 2

Frequent Collaborators

2 joint publications

Zuhayr Jafri

2 joint publications

Tatsuya Yoshida

2 joint publications

Hossein Borghaei

2 joint publications

Levon M Khachigian